Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The Department of Paediatrics offers a number of opportunities for post-graduate research programmes, leading to a D.Phil in Paediatrics.

The Department has major interests in developmental immunology, infectious diseases of infancy and childhood, HIV infection and immune control, design, development and testing of vaccines, and in paediatric molecular genetics. Subject areas cover a large spectrum of paediatric medical, and scientific research.

Details of available DPhil projects can be found  here.



There is an open field period for applications received after the 10th January 2020 for entry in October 2020 and such applications will not be considered for the departmental studentships. Please contact individual supervisors to discuss your application and research proposal before submitting an application. Such applicants will need to have independently secured awards or private funding.

Applicants in the open field need to apply for the programme via the main University graduate application form.

To access the application form and application guide, please go to:

Application Guide;

Application Form;


Course code (RD_PE1)

For further information, please see the Medical Sciences web pages:



A doctorate is an important step in any clinical academic career. At any one time, numerous doctors are undertaking a DPhil at Oxford. Read more on the Oxford University Clinical Academic Graduate School DPhil page here.



For Oxford PGT students wishing to undertake a D.Phil in Paediatrics, please refer to



Please read the following information on the main University pages carefully before accepting an offer from us.



Please contact if you have any enquiries.


The Department of Paediatrics offers a variety of doctoral opportunities across its research themes. Take a look at the outlines of prospective DPhil projects - and please get in touch with the relevant supervisor to discuss the details.

Impact of immunisation on pharyngeal carriage of meningococcus and pneumococcus

Efficacy and correlates of protection with a new paratyphoid vaccine in a controlled human infection model

Supervisor: Professor Andrew Pollard

The project will examine the potential efficacy of a new paratyphoid vaccine using a controlled human infection model. Human volunteers will be vaccinated with a new paratyphoid vaccine and then challenged with wild-type Salmonella Paratyphi by mouth in a bicarbonate solution. The volunteers will be closely monitored for 2 weeks, and treated either on developing infection or at 2 weeks if no infection is detected. We will examine antibody and cellular responses to ascertain the immune mechanisms associated with protection. The study will involve state-of-the-art cellular and serological techniques to provide new insights into immunity against this neglected disease.

Contact details: Andrew Pollard  

Applications by: 10th January 2020

Further information: The Oxford Vaccine Group is an interdisciplinary research environment with expertise form vaccine design and development through translation in to human studies, through phase 1-IV clinical evaluation and human challenge studies, and vaccine evaluation in the laboratory using state pf the art technology. Work on enteric fever is a major focus of the group with the aim of improving health among some of the most vulnerable populations through vaccine prevention of typhoid and paratyphoid.

Jin, C., Gibani MM, Moore M, Juel HB, Jones E, Meiring J, Harris V, Gardner J, Nebykova A, Kerridge SA, Hill J, Thomaides-Brears H, Blohmke CJ, Yu LM, Angus B and A. J. Pollard (2017). "Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial." Lancet 2017 Dec 2;390(10111):2472-2480


Functional properties of typhoid antibodies in endemic and non-endemic populations

Supervisor(s): Professor Andrew Pollard and Dr Jennifer Hill

Project outline: Antibodies against the Vi capsular polysaccharide of Salmonella Typhi generated in response to vaccination are protective against infection. Early indications from a human challenge study suggest IgA and antibody-mediated neutrophil phagocytosis of bacteria in particular may be highly important in conferring protection. Using high throughput antibody functionality assays, profiles following typhoid vaccination both in endemic and non-endemic populations will be explored. The project will test whether environmental exposure to S. Typhi and repeated vaccination result in maturation of effector profiles, and identify potential population differences in vaccine response. These data will support assessment of the impact of vaccination programs globally as well as shedding light on factors involved in antibody effector profile maturation.

Contact details: Jennifer Hill

Applications by: 11th January 2019

Further information: The Oxford Vaccine Group (OVG) carries out research into novel vaccines to prevent infectious diseases. Uniquely OVG conducts human challenge studies for typhoid and paratyphoid in order to accelerate vaccine development and facilitate exploration of the immunology of infection. In addition the group is a member of consortia involved in overseas typhoid surveillance and vaccination trials; well positioned to explore findings from human challenge trials in (para)typhoid endemic populations and vice versa.

Jin, C., Gibani MM, Moore M, Juel HB, Jones E, Meiring J, Harris V, Gardner J, Nebykova A, Kerridge SA, Hill J, Thomaides-Brears H, Blohmke CJ, Yu LM, Angus B and A. J. Pollard (2017). "Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial." Lancet 2017 Dec 2;390(10111):2472-2480



Development of a novel vaccine to protect against plague: exploration of optimal viral vectored vaccines use in humans

Supervisor: Dr Christine Rollier  

Project outline: The Oxford Vaccine Group has created a novel vaccine to tackle plague epidemics, based on the use of an adenovirus vectored platform. The new vaccine will be entering phase I clinical trial in September 2019, to assess its safety and immunogenicity in healthy adults. We will test the hypothesis that a single dose is sufficient to induce functional immune responses in naives individuals, and characterise the innate immune signals associated with immunogenicity. In this project, we will also investigate new delivery modalities, including mucosal needle-free delivery platforms and judicious prime-boosting approaches that may be critical in extending the use of this vaccine platform in humans.

The project involves techniques in human immunology using a range of established and cutting edge technologies, combining ex vivo and in vitro experiments, and including fluorospot (B and T-cell responses), flow cytometry, neutralisation assays. The ultimate aim is to progress an innovative vaccine to prevent infections caused by Y. pestis (the plague) to the target populations.  

Contact details: Christine Rollier 

Applications by: 11th January 2019

Further information: The focus of the group is the pre-clinical and early clinical development of new or improved vaccines against infectious diseases affecting vulnerable populations (children and developing countries), and if successful to progress these vaccines to clinical development (GMP production and clinical trials). We aim to understand the mechanisms supporting the induction of functional and protective antibody responses using different vaccine technologies against the bacterial diseases. 

Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol. 2016 Aug;41:47-54. doi: 10.1016/j.coi.2016.05.014.


Immunopathogenesis of TB/HIV in Children

Supervisor: Dr. Rinn Song

Project outline: Compared to adults, young children are more likely to progress to active TB, including severe clinical manifestations. The immunologic mechanisms for this age-dependent susceptibility to TB are not yet fully understood. In addition to young age, HIV-infection is the other major predisposing factor associated with higher susceptibility to TB. Despite the substantial number of HIV-infected children globally, many of them living in TB-endemic areas, their immunopathophysiology is largely unexplored. In a comprehensive study in Kampala, we aim to delineate differences in innate and adaptive immunity in Ugandan children with TB and latent TB infection, stratified by their HIV status.

Contact details: Rinn Song

Applications by: 11th January 2019


DPhil opportunities in  the Holländer lab

Supervisor: Prof. Georg Holländer

Background information: T cells are essential for the generation and resolution of an adaptive immune response as they orchestrate an individual’s critical capacity to distinguish between benign self and harmful non-self antigens. Exclusively formed in the thymus, T cells rely during their development on the continuous physical and functional proximity to thymic epithelial cells (TEC), the major stromal component of the thymus. TEC instruct haematopoietic cells to adopt a T cell lineage fate, expand, mature and be selected according to their antigen-receptor specificity to become functionally competent T cells that can exit the thymus to the periphery. Maturing T cells gain the competence to remain tolerant (i.e. non-responsive) when exposed to and recognising an individual’s own antigens while the same cells - as a population - remain completely responsive to all other antigens. For this capacity to be correctly instructed, TEC express practically all of an individual’s protein-coding genes via a process designated promiscuous gene expression and thus present a comprehensive library of self-antigens to developing T cells. 


Project outlines: Given the central importance of TEC for thymus function, the laboratory of Developmental Immunology is focusing its research on the genetic programmes and the epigenetic mechanisms that control TEC differentiation, maintenance and function. Present projects open for DPhil projects focus on

  1. The structure and function of the TEC-autonomous master regulator FOXN1: This transcription factor belongs to a large family of forkhead molecules which are very well preserved across many vertebrate species. Mutations in FOXN1 in humans, mice and others are the genetic cause of a lack of normal TEC formation and a complete absence of T cells and thus an adaptive immune system that is operative. FOXN1 structure::function analyses are carried out following the identification of several patients with single heterozygous, compound heterozygous or homozygous mutations in the coding sequence of this transcription factor in patients diagnosed to lack a normal complement of functional T cells. To test specific FOXN1 mutations in vivo, mouse models have been created that allow a detailed analysis of the consequences of mutant FOXN1 for thymus development and function.
  2. The competence of TEC to express almost all of an individual’s protein-coding genes: This capacity unique to TEC is in part accomplished by the presence of the transcriptional facilitator AutoImmune REgulator, AIRE. AIRE-regulated gene transcription is marked by repressive chromatin modifications, including H3K27me3. Mice have been generated and will be analysed for their capacity of promiscuous gene expression as they have gain- or loss-of-function mutations affecting the placement of post-translational histone modifications.
  3. The role of the haploid loss of the Tbx1 and Crkl genes resulting in the 22q11 Deletion Syndrome (previously named DiGeorge Syndrome) characterised by a complex phenotype including the absence of regular TEC formation and function. A mouse model has been created that genetically mimics the the 22q11 Deletion Syndrome exclusiverly to TECs and thus allows a detailed molecular and cellular analysis of the cells’ bioloigy in the absence of TBX1and CRKL.


Contact details: Sabrina Harris

Applications by: 11th January 2019


Imaging pain in the developing human brain


Supervisor: Professor Rebeccah Slater and Dr Eugene Duff

Project outline: Little is known about how and when the human infant develops the ability to perceive and modulate pain. In adults, verbal report can quantify individual pain experience and assess analgesic efficacy, whereas in the infant, reliance on surrogate measures is necessary to infer pain perception. As cortical activation is a fundamental requirement for an experience to be interpreted as painful, inferences based on brain activity patterns may provide the most reliable surrogate measures. Building on recent advances in adult brain imaging, the aim of this project will be to adapt and advance these methods for use in the developing brain to create reliable and sensitive age dependent measures of infant pain. 

Contact details: Rebeccah Slater

Applications by: 4th January 2019

Further information: The focus of the lab is to undertake a series of mechanistic studies in human infants to enhance understanding of the developing central nervous system (CNS), provide insights into how the environment shapes CNS function during early development, and improve understanding and treatment of infant pain.



The impact of apnoea on brain activity in preterm infants


Supervisor: Dr Caroline Hartley

Project outline: Apnoea - the cessation of breathing - is a common pathology associated with prematurity. These potentially life-threatening events can result in reduced cerebral oxygenation and frequent apnoeas have been associated with long-term effects including reduced childhood cognitive ability. Brain activity drives brain development during the critical preterm period but the immediate impact of apnoeas on brain activity is not well understood. The aim of this project will be to characterise the relationship between apnoeas and brain activity in preterm infants, and how this changes with development. EEG (electroencephalography) and physiology will be recorded simultaneously, and signal processing approaches will be used and developed to fully characterise this relationship. This research will enhance our understanding of apnoeas, and ultimately seeks to improve outcomes for prematurely-born children.

Contact details:

Applications by: 10th January 2020

Further information: The focus of the lab is to understand the impact of physiological instability on brain development in premature infants. 1 in every 10 babies are born prematurely; understanding and mitigating the long-term impact of premature birth is important to improve the lives of these children. We develop novel methodologies with the aim to provide a greater understanding of infant brain development and derive tools which can be translated to the clinical setting.

Intestinal inflammation and primary immunodeficiency


Supervisor: Professor Holm Uhlig

Project outline: Inflammatory bowel diseases (IBD) are a complex group of disorders with genetic predisposition. A minority of patients harbour extremely rare generic variants associated with Mendelian disorders. Maladaptation of the intestinal host microbial cross-talk towards intestinal bacteria can result in inflammatory bowel disease. Intestinal macrophages are key in this process since these cells phagocytose and remove translocating bacteria under homeostatic conditions without causing inflammation, whereas monocytes and monocyte derived macrophages can be major contributors of inflammatory cytokines if tolerance is broken. A genetically informed mechanistic concept of IBD suggests that immunosuppressive and anti-cytokine strategies should be combined with reinstalling of antimicrobial activity to induce and/or maintain remission. This project aims to characterise intestinal macrophage differentiation  and antimicrobial activity in patients with Mendelian forms if intestinal inflammation. A functional genomic approach characterising the functional effects of rare variants via technologies such as  single cell sequencing, proteomics and in vitro infection models will allow to understand key aspects of defective autophagy and resulting hyperinflammatory responses in those patients.

Contact details:

Applications by: 3rd January 2020

Further information: The focus of the lab is to understand rare genetic defects that affect key mechanisms of the intestinal barrier function. We aim to understand patients that develop intestinal inflammation due to Mendelian disorders as proof of concept and understand how those mechanisms can direct novel diagnostics and treatments as well as inform on more common forms of intestinal inflammation (Uhlig & Powrie Annual Review Immunology 2018).




Supervisor: Professor Matthew Snape

Project outline: Prof Snape invites students to contact him directly to discuss possible projects.

Contact details:

Applications by: 10th January 2020

Further information: Prof. Snape's principal areas of research relate to vaccines against meningococcal, pneumococcal, influenza, RSV and Ebola virus disease. In 2014/2015 he was the lead investigator on a 'first in human' phase 1 study of a candidate ebola vaccine, providing data crucial to the planning of subsequent studies in West Africa. He is currently the Chief Investigator of the 'Be on the TEAM' study enrolling 24 000 Year 12 students to evaluate the impact of immunisation with group B meningococcal vaccines on pharnygeal carriage of meningococcus, and is the Director of the National Immunisation Schedule Evaluation Consortium (NISEC), both of which are NIHR funded. Other projects include leading on the instigation of the Global Platform for Prevention of Autoimmune Diabetes (GPPAD) in the UK and acting as a Chief or Principal Investigator on clinical trials of multiple RSV vaccine candidates.


Exploring the early response to (para)typhoid exposure in a human challenge model of infection

Student name: Amber Barton

Supervisors: Professor Andrew Pollard, Dr Jennifer Hill and Dr Irina Mohorianu

Description: Several plasma cytokines have been found to transiently increase around 12 hours after healthy volunteers are experimentally exposed to Salmonella Typhi, regardless of whether they go on to develop signs of infection. This raises a number of questions, including the identity and location of the cells producing these cytokines, whether we can detect other immunological signatures of exposure, and whether such signatures differ between those who become infected and those who remain well. In this project these questions are being addressed using whole blood transcriptional analysis. Early differences in the transcriptome between individuals who remain well and those who develop disease have indicated genes which might be involved in protection.  Furthermore, gene set enrichment analysis of blood transcriptional changes occurring 12 h post-exposure has allowed characterisation of early cellular responses, the significance of which is being investigated further with in vitro experiments.

Source of funding: St Cross Paediatrics Scholarship (Department of Paediatrics and St Cross College), with project support from Wellcome Trust and the Bill and Melinda Gates Foundation.

Further information:

Blohmke, C. et al. (2016) Interferon-driven alterations of the host’s amino acid metabolism in the pathogenesis of typhoid fever. Journal of Experimental Medicine.


Evaluating the effect of immunisation with capsular group B meningococcal vaccines on meningococcal carriage

Student name:  Jeremy Carr

Supervisors:  Dr Matthew Snape; Professor Martin Maiden

Description:  Capsular group B meningococcal (MenB) vaccines provide direct protection against invasive MenB disease, however the effect on herd protection is not known. This study will evaluate the influence of MenB immunisation on oropharyngeal carriage in teenagers, and consequently the potential for these vaccines to disrupt transmission and provide broad community protection against MenB disease. Given the potential for immunisation with the subcapsular protein antigens in MenB vaccines to impact on the carriage of non-MenB pathogenic and commensal Neisseria species, carriage rates of these organisms will also be evaluated. Understanding the influence of MenB protein-based vaccines on herd protection will inform current vaccine policy and future vaccine development.

Source of funding:  University of Oxford; Clarendon Scholarship; National Institute for Health Research; Department of Health.  

Further information:


Assessing the immune mechanisms underlying the immunogenicity to meningococcal group B vaccines

Student nameDylan Sheerin

Supervisors: Prof. Andrew Pollard, Dr Christina Dold, Dr Christine Rollier

Description: The Gram-negative bacterium Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD), a severe bacterial infection which occurs predominantly in infants within the first years of life. Two meningococcus group B (MenB) vaccines have been licensed, but both have significant drawbacks. A novel MenB vaccine has been developed at the Oxford Vaccine Group, based on a viral vector. The vaccine candidate induced strong and persistent protective immune responses in mice after a single dose, and a phase I trial to assess its safety and immunogenicity in healthy adults is ongoing. The D.Phil student is working on understanding the mechanisms which underlie the responses induced by these distinct vaccines at the genetic, cellular and systems level, and the results will contribute to the rational design of future vaccine candidates for MenB and other bacterial diseases. 

Source of funding: Medical Research Council

Further information: Currently in second year.


RaPaed-TB: Evaluation of New Diagnostics in Childhood TB


Student name: Laura Olbrich

Supervisor: Professor Andrew Pollard; Dr. Rinn Song

Description: Globally, children account for an estimated one million TB cases and more then 200,000 deaths due to TB per year. The main challenge is adequate and timely diagnosis as currently available diagnostic tests fail to diagnose the majority of children with TB. New testing strategies are therefore urgently needed. In a prospective, multi-country clinical study in four African countries and in India, diagnostic performance data on a number of promising novel assays and sampling strategies will be generated. In addition, the study will derive diagnostic and screening algorithms for TB using existing and these novel tests.

Source of funding: EDCTP